NAMS
NewAmsterdam Pharma Company N.V.
24.30$
+2.1%
vs. previous close
Closing price · As of: Sep 30, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | – | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | 0.1% | 0.3% | 0.2% | 0.3% | |
| – | – | 100.0% | 100.0% | 100.0% | 99.7% | |
| – | – | 84.5% | 1,131.5% | 332.3% | 630.3% | |
| – | – | 19.0% | 267.1% | 154.6% | 472.4% | |
| – | – | 103.5% | 1,398.6% | 486.9% | 1,102.6% | |
| – | – | -3.5% | -1,298.6% | -386.9% | -1,002.9% | |
| – | – | 0.3% | 48.3% | 0.0% | – | |
| – | – | -22.0% | -1,255.6% | -530.3% | -905.7% | |
| – | – | 69.0% | 0.2% | 0.0% | – | |
| – | – | -22.0% | -1,255.8% | -530.3% | -905.7% | |
| – | – | -21.8% | -1,255.2% | -530.0% | -1,076.9% |
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.